Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Asset Resilience Ratio
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has an Asset Resilience Ratio of 34.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Wuhan Easy Diagnosis Biomedicine Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's Asset Resilience Ratio has changed over time. See net asset quality index of Wuhan Easy Diagnosis Biomedicine Co Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Wuhan Easy Diagnosis Biomedicine Co Ltd (002932) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.07 Billion | 34.47% |
| Total Liquid Assets | CN¥2.07 Billion | 34.47% |
Asset Resilience Insights
- Very High Liquidity: Wuhan Easy Diagnosis Biomedicine Co Ltd Class A maintains exceptional liquid asset reserves at 34.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
Annual Asset Resilience Ratio for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.59% | CN¥394.35 Million ≈ $57.71 Million |
CN¥5.98 Billion ≈ $875.11 Million |
+5.62pp |
| 2024-12-31 | 0.97% | CN¥64.12 Million ≈ $9.38 Million |
CN¥6.59 Billion ≈ $964.77 Million |
-0.69pp |
| 2023-12-31 | 1.66% | CN¥122.59 Million ≈ $17.94 Million |
CN¥7.39 Billion ≈ $1.08 Billion |
-19.59pp |
| 2022-12-31 | 21.25% | CN¥1.95 Billion ≈ $285.75 Million |
CN¥9.19 Billion ≈ $1.34 Billion |
+0.76pp |
| 2021-12-31 | 20.49% | CN¥700.00 Million ≈ $102.43 Million |
CN¥3.42 Billion ≈ $500.03 Million |
+6.47pp |
| 2020-12-31 | 14.02% | CN¥200.00 Million ≈ $29.27 Million |
CN¥1.43 Billion ≈ $208.76 Million |
-17.31pp |
| 2019-12-31 | 31.33% | CN¥200.00 Million ≈ $29.27 Million |
CN¥638.42 Million ≈ $93.42 Million |
-- |
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more